Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
NCT05461664 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 74
Last updated 2025-02-26
Summary
This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.
Conditions
- Gastrointestinal Stromal Tumors
- Unresectable Solid Tumor
- Recurrent Metastatic Malignant Neoplasm
Sponsors & Collaborators
-
Peking University Cancer Hospital & Institute
collaborator OTHER -
Fudan University
collaborator OTHER -
Peking University People's Hospital
collaborator OTHER -
Chinese PLA General Hospital
collaborator OTHER -
Xiangya Hospital of Central South University
collaborator OTHER -
Peking University Shenzhen Hospital
collaborator OTHER -
Nanfang Hospital, Southern Medical University
collaborator OTHER -
West China Hospital
collaborator OTHER -
Jiangsu Cancer Institute & Hospital
collaborator OTHER -
Shanghai Zhongshan Hospital
collaborator OTHER -
Sun Yat-sen University
collaborator OTHER -
Xijing Hospital
collaborator OTHER -
Shengjing Hospital
collaborator OTHER -
Shanghai Jiao Tong University School of Medicine
collaborator OTHER -
Liaoning Cancer Hospital & Institute
collaborator OTHER -
Sixth Affiliated Hospital, Sun Yat-sen University
collaborator OTHER -
Fujian Medical University Union Hospital
collaborator OTHER -
Cancer Hospital of Guangxi Medical University
collaborator OTHER -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
collaborator OTHER -
First Affiliated Hospital of Chongqing Medical University
collaborator OTHER -
Chongqing University Cancer Hospital
collaborator OTHER -
Xinhua Zhang, MD
lead OTHER
Principal Investigators
-
Xinhua Zhang, PhD · First affiliated hosptial,Sun Yat-sen university
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-10
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer
NCT06608537 ·Status: COMPLETED ·Phase: PHASE2
-
Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment
NCT02860234 ·Status: COMPLETED
-
Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
NCT07014254 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052 ·Status: NOT_YET_RECRUITING
-
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
NCT05148767 ·Status: RECRUITING ·Phase: PHASE4
-
Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-
NCT06895577 ·Status: WITHDRAWN ·Phase: PHASE2
-
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
NCT05385549 ·Status: RECRUITING ·Phase: PHASE2
-
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
NCT03177382 ·Status: UNKNOWN ·Phase: PHASE3
-
A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk
NCT04664504 ·Status: RECRUITING ·Phase: PHASE2
-
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
NCT04405206 ·Status: UNKNOWN
-
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
NCT06504901 ·Status: NOT_YET_RECRUITING
-
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT02031939 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Observational Study on the Patients With Rectal Cancer
NCT02312284 ·Status: COMPLETED
-
PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer
NCT06933251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
NCT06210971 ·Status: RECRUITING ·Phase: PHASE2
-
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
NCT02453490 ·Status: TERMINATED ·Phase: PHASE3
-
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
NCT07214142 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer
NCT05023720 ·Status: UNKNOWN
-
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
NCT07104604 ·Status: RECRUITING ·Phase: PHASE1
-
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
NCT06204094 ·Status: RECRUITING ·Phase: PHASE2
-
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
NCT06613165 ·Status: RECRUITING
-
Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
NCT02605265 ·Status: COMPLETED ·Phase: PHASE3
-
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
NCT04835324 ·Status: UNKNOWN
-
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
NCT06764680 ·Status: RECRUITING ·Phase: PHASE2
-
Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
NCT07161115 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2